Boston Scientific(US:BSX) Ge Long Hui A P P·2025-10-22 13:16Core Viewpoint - Boston Scientific reported a strong third-quarter performance with a 20% year-over-year sales growth, reaching $5.07 billion, surpassing Wall Street's expectations of $4.97 billion [1] Group 1: Financial Performance - The cardiovascular segment achieved a 22% year-over-year sales increase, totaling $3.34 billion, exceeding the anticipated $3.27 billion [1] - Adjusted earnings per share (EPS) for the quarter were $0.75, higher than the expected $0.71 [1] Group 2: Future Guidance - For the fourth quarter, the company projects EPS to be between $0.77 and $0.79, compared to analyst expectations of $0.76 [1] - The full-year adjusted EPS guidance has been raised from a range of $2.95 to $2.99 to a new range of $3.02 to $3.04, while analysts had anticipated $2.98 [1]